checkmate 816 trial: nivolumab platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...
Published 3 years ago • 347 plays • Length 6:04Download video MP4
Download video MP3
Similar videos
-
7:23
surgical outcomes from checkmate 816: nivo plus chemo vs chemo alone as neoadjuvant treatment fo...
-
2:07
checkmate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-io
-
3:23
surgical outcomes from the phase iii checkmate 816 trial
-
3:25
checkmate 816: neoadjuvant nivolumab chemotherapy for nsclc - onctalk lung 2023
-
5:10
neoadjuvant nivolumab chemo continues to provide long-term clinical benefit for nsclc patients
-
11:30
asco 2021 lung recap: surgical outcomes & checkmate 816: nivolumab in early stage nsclc
-
8:13
checkmate 816: combining chemo and opdivo - asco lung review 2022
-
2:35
checkmate-816: what does the data tell us?
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
10:12
nivolumab ipilimumab 2 cycles of platinum-doublet chemo vs 4 cycles chemo for stage iv nsclc
-
2:01
upcoming nsclc trials in 2022: checkmate 816 & keynote-091
-
1:10
event-free survival results from checkmate 816
-
4:05
checkmate 9la: first-line nivolumab ipilimumab 2 cycles chemotherapy vs 4 cycles chemo in an...
-
3:44
immunotherapy as combination and neoadjuvant therapies in nsclc
-
8:45
nivolumab ipilimumab vs platinum-doublet chemotherapy as first-line treatment for advanced nsclc
-
0:48
the rationale and trial design of the nadim ii trial
-
2:33
checkmate 227: chemo-free nsclc treatment
-
12:35
the checkmate 816 trial: the success of adjuvant nsclc therapies - lung cancer onctalk 2022
-
3:16
perioperative therapies in nsclc